Articles tagged with Drug Targets
A study by Texas A&M University found that pregaming is linked to unsafe alcohol use and other risky behaviors among college students. Pregaming was associated with a two-day increase in alcohol use frequency and was found to be around 2.5 times more likely to lead to cannabis or other drug use.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
A new targeted treatment called zolbetuximab has been shown to extend survival for patients with advanced gastric or gastroesophageal junction cancer that overexpresses a specific biomarker. The treatment significantly increased progression-free and overall survival, with improved results compared to standard chemotherapy.
Imperial researchers have imaged Piezo1 channels in human cells and organs, revealing their role in regulating blood pressure, respiration, bladder control, and the immune system. This breakthrough could lead to a better understanding of their role in fundamental physiological processes and potentially new drug targets for diseases.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers identified a new approach to treat poxviruses by targeting a cellular protein, making the virus more susceptible to natural defences. Existing immunosuppressive drugs can restrict replication and spread of poxviruses.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Research reveals that high blood pressure disrupts artery cell messaging, causing arteries to remain constricted and limiting blood flow to the brain. The study provides a potential route for developing first-ever drug treatments for vascular dementia.
Researchers have developed novel liquid metal nanoparticles that combine photothermal therapy with immunotherapy, demonstrating high specificity and low side effects. The nanoparticles can target and destroy cancer cells while also stimulating the immune system to fight against tumors.
Researchers propose GABA-modulating treatments as potential therapeutic targets for depression's cognitive and affective symptoms. The study highlights the importance of GABA-A receptors in regulating balance and signals between neurons, and suggests compounds that promote or inhibit these receptors may alleviate depressive symptoms.
Researchers have identified a novel therapeutic target for pelvic pain in endometriosis by focusing on the IL-1β pathway and its regulation via the JNK signaling pathway. This study suggests that JNK inhibitors may be effective in reducing neuroinflammation and alleviating symptoms of endometriosis-associated pain.
A new study from the University of Missouri found that poverty, low health literacy, cultural beliefs, lack of infrastructure, and political issues hinder diabetes self-management for Haitian migrants. The researchers suggest targeted interventions, such as community gardens and healthcare education through local priests.
A study published in Science reveals that ganglia in the neck region are responsible for disrupting melatonin production and causing sleep disturbances in people with heart conditions. Researchers found that macrophages accumulate in the ganglion, leading to inflammation and scarring, which can be treated with drugs.
The American Heart Association and the American College of Cardiology recommend a heart-healthy diet and lifestyle to prevent worsening health in people with chronic coronary disease. Clinicians should coordinate care between cardiovascular and primary care professionals, emphasizing team-based approach and social determinants of health.
Researchers from Osaka University found that RNase treatments can either enhance or weaken immune activation in systemic autoimmune diseases. The study suggests that the composition of immune complexes plays a crucial role in determining the effectiveness of RNase treatment.
Researchers from Osaka University identified ten blood proteins associated with mortality in severe burns, including HBA1, TTR, and SERPINF2. These proteins may serve as targets for developing new treatment methods for burns, offering a promising direction for future research.
A study reveals high levels of insecticide resistance among Aedes aegypti populations in Dhaka, compromising mosquito control and increasing dengue burden. Researchers recommend non-insecticidal approaches, such as Wolbachia-infected mosquitoes, to effectively manage dengue vectors.
Researchers at UCLA Jonsson Comprehensive Cancer Center confirmed genetic variants of unknown significance are verified mutations that increase the risk of kidney cancer. The findings could lead to new treatment options for people with hereditary leiomyomatosis and renal cell cancer (HLRCC).
Mass General Cancer Center researchers have pinpointed the APOBEC3A protein as a primary driver of drug resistance in non-small-cell lung cancer. The study reveals that this protein causes mutations and accelerates tumor growth, making it a promising target for new therapies.
Researchers at Texas A&M University found that substance use impairs cognitive flexibility by inhibiting specific neurons. Chronic cocaine or alcohol use alters the local inhibitory brain circuit, leading to decreased cognitive flexibility and increased risk of academic deficits and lower quality of life.
Researchers at the University of Virginia Health System have identified a novel mechanism by which hair cells can repair themselves after damage. This breakthrough understanding has the potential to develop new treatments for age-related hearing loss and other conditions.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Research leaders collaborate with organizations and regulators to develop digital tools for Parkinson's clinical trials. The Digital Drug Development Tools initiative accelerates the regulatory endorsement of these tools, enabling more objective and patient-centered measures.
Scientists at Tokyo Institute of Technology identified ApSigma, a nuclear-encoded apicoplast RNA polymerase σ subunit that coordinates gene expression with the life cycle of Plasmodium falciparum and host circadian rhythm. Melatonin is shown to increase apicoplast transcription and expression of the apSig gene.
A new study has identified 16 new locations in the genome linked to immunoglobulin A (IgA) nephropathy, a common kidney disease. The research confirms an earlier hypothesis that the immune system plays a key role in driving the disease and provides potential drug targets for treatment.
Researchers aim to identify best practices for increasing viral suppression in low-income populations with HIV. They will examine state AIDS Drug Assistance Programs to understand disparities in care and outcomes.
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
Peruvoside has been discovered to prevent up to 12 medically important viruses, including SARS-CoV-2, Hand, Foot and Mouth Disease (HFMD), and Influenza. The compound acts on GBF1 protein, disabling its functionality and stopping virus production.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
UCF researcher Dr. Justine Tigno-Aranjuez has discovered a new receptor that recognizes house dust mite allergens, opening up potential for broad-spectrum therapy. The finding could lead to improved treatments for common allergies, including asthma.
The FDA has issued a Biomarker Letter of Support for four novel biomarkers identifying drug-induced pancreatic injury. These microRNAs will enhance the detection of acute drug-induced pancreatic injury (DIPI) in phase 1 clinical trials, improving safety and accuracy.
A new study reveals that only one in four adolescent residential treatment centers across the US provides buprenorphine, a proven tool in fighting opioid addiction. The lack of access to this medication undercuts US efforts to alleviate the overdose epidemic, which claimed over 109,000 lives in 2022.
Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.
Researchers discovered that targeting specific blood vessel enzymes can enhance immunotherapy effectiveness and prevent breast cancer metastasis. By disabling the enzyme DNMT1 in blood vessels, doctors may bolster anti-tumor immune cells entry and increase patients' response to treatment.
The study found that the immune response to spinal-cord injuries is impaired in older individuals, leading to weaker cell responses and reduced recovery. The researchers identified an essential role for the meninges surrounding the spinal cord in mounting the immune response, paving the way for new therapeutic approaches.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
Researchers updated their protein localization prediction model, MULocDeep, to provide more targeted predictions for biological discoveries. The tool helps researchers design more effective experiments and advance scientific discoveries related to drug development and treating diseases like epilepsy.
Researchers from St. Jude Children's Research Hospital discovered NLRP12 to be the key molecule responsible for inducing inflammatory cell death and pathology in response to heme combined with other cellular damage or infection. This finding provides a new potential drug target to prevent morbidity in certain illnesses.
A study published in Brain Behavior and Immunity found autoantibodies against a synaptic adhesion protein, neurexin 1α, in patients with schizophrenia. In mice, these autoantibodies caused schizophrenia-related changes, including reduced social behavior and cognitive function.
Researchers have found that stimulating a specific bile acid receptor, FXR, may help prevent retinopathy of prematurity in premature babies. By targeting this receptor, the study aims to develop earlier and more effective treatments to protect their vision.
A team of researchers at Johannes Gutenberg University Mainz studied the collective behavior of small robots and found that they can solve tasks that a single machine cannot. The study uses statistical physics to analyze how the robots interact and move, revealing potential applications in medical and pharmaceutical applications.
A new potential drug target has been identified for Alzheimer's disease by Rensselaer researchers, focusing on the interaction between ApoE and heparan sulfate. The study suggests that modulating this interaction could slow the progression of the disease.
Researchers at UCL have uncovered the molecular basis of a woman's rare genetic mutation that allows her to live pain-free and heal rapidly. The study found that the mutation in the FAAH-OUT gene turns down FAAH gene expression, affecting other molecular pathways linked to wound healing and mood.
A team of researchers at NYU College of Dentistry has successfully modified an existing anti-nausea drug to target the endosomes within cells, thereby providing a more prolonged analgesic effect. The modified netupitant showed improved pain-relieving properties compared to its original form and other drugs targeting similar receptors.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Scientists have identified a key event controlling the timing of biological clocks, which could lead to therapies for sleep disorders and clock disruption. The study found that a genetic mutation shortens the clock cycle in people with Familial Advanced Sleep Phase Syndrome.
Researchers identified novel genetic associations between AD and modifiable risk factors, including high HDL cholesterol concentrations and systolic blood pressure. These findings may inspire new drug targets and improved prevention strategies for AD.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Scientists have developed a gene-editing technique that allows them to easily engineer specific cancer-linked mutations into mouse models. This new method, based on CRISPR genome-editing technology, enables researchers to explore many unknown mutations and develop new drugs targeting those mutations.
A study published in Stroke identified two proteins, R-spondin 3 (RSPO3) and LGR4, that trigger a signaling pathway to reduce inflammation and promote neurite outgrowth in the ischemic brain. This discovery provides new hope for patients with ischemic stroke by targeting RSPO3/LGR4 signaling.
Researchers have engineered a new CRISPR-based drug candidate targeting E. coli directly while preserving the microbiome. The innovative treatment has shown promise in reducing E. coli burden in mice and is now in phase 1 clinical trials to treat blood cancer patients and prevent deadly infections.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
Researchers have developed a modular system to recognize chiral molecules, which could lead to more effective methods of separating enantiomers in drugs. The system uses metallopolymers with chirality to sense two enantiomeric molecules through electrochemical interactions.
Researchers developed NetBID2 to analyze multi-omics data and find hidden druggable targets in cancer. The tool successfully identified previously unappreciated roles for genes like MYC and NOTCH1 in adult lung cancer and pediatric leukemia, highlighting its potential for accelerating clinical trials.
Researchers found that when FXR1 is absent, vascular smooth muscle cells proliferate more slowly, become senescent, and scar tissue development is reduced. This suggests that drugs targeting FXR1 may treat vascular proliferative diseases such as atherosclerosis, restenosis, hypertension, and abdominal aortic aneurysm.
Researchers have identified 11 somatic mutations in the RAS/MAPK pathway that contribute to treatment-resistant adult epilepsy, suggesting the potential for repurposed anti-cancer agents as new treatments. This study provides insight into the genetic mechanisms underlying this form of epilepsy and opens up new avenues for targeted ther...
Researchers at Nagoya University have successfully developed an ultrafast and simple synthetic method for producing indole derivatives. The new microflow synthesis method enables precise control of short reaction times, limiting unwanted dimerization/multimerization and increasing the yield of desired products.
Researchers at UCL have identified proteins in the blood associated with an increased risk of developing heart diseases, including heart failure. The findings could lead to more refined cancer treatments that minimize cardiotoxicity and improve survival rates.